Sina Medicine Live Lesson 9 The breakthrough in the administration of myopia treatment drugs

In recent years, pharmaceutical industry policies have been introduced, consistent evaluation, China's accession to ICH, MAH implementation, drug clinical trial data verification and other accelerated industry survival of the fittest;
the reform of medical policy, the development of China's pharmaceutical industry is entering the fast track of norms.
the context of the rise of "healthy China" as a national strategy, China is undergoing a transformation from a "medical power" to a "medical power".
biopharmaceutical industry, as one of china's seven strategic emerging industries, is becoming a new engine of China's economic development.
through policy regulation, investment of supporting resources and improvement of institutional mechanism construction, China's biopharmaceutical industry has transitioned from "technological backwardness" to "following the international pace", in which the development of innovative drugs is particularly rapid.
has emerged a number of innovative biopharmaceutical companies, such as Baiji Shenzhou, Xinda Bio, No cheng Jianhua and so on, as well as independent research and development of innovative drugs approved for market.
to sustain rapid growth, more top talent will be needed and the overall level of employees will be improved.
In order to provide innovative pharmaceutical practitioners with a free and smooth exchange platform, Sina Pharmaceuticals has launched a "New Zhihui" online live knowledge sharing platform, which will focus on hot topics such as target discovery, new technology development and application, process development and verification, drug clinical trial design, and so on, through strategy and case sharing, directly hit the confusion in research and development production.
Thuring Wednesday, November 25th, the 9th lesson of "New Zhihui" weighs in, and Dr. Qing Liu, Vice President of Clinical Development and Registration of Arctic Vision Polar Vision, will share with you "a breakthrough in the administration of nearshed-sighted therapeutic drugs" and look forward to your participation.
Share theme: Myopia treatment drug administration technology breakthrough 1, the harm of children's myopia and existing therapy profile 2, low concentration of Athosin research and development process 3, "micro-matrix membrane" black technology for Atho products to bring breakthrough presenter: Dr. Liu Qing Arctic Vision polar biological clinical development Live Time: November 25, 2020 19:30-20:30 Dr. Liu Qing, Vice President of Clinical Development and Registration of Polar Vision Polar Vision, Dr. Liu Qing has 16 years of experience in the field of ophthalmology, including clinical, scientific research and industry.
prior to joining Polar Creatures, she was The Head of Clinical Development and Medical Affairs in Greater China, The Medical Director of Elcon Asia Pacific, and the Head of Ophthalmology in Eljian China, and the Head of Glare Ophthalmology in Eljian Asia Pacific, leading the successful development and launch of a wide range of ophthalmology drugs, medical devices and OTC products.
After receiving comprehensive clinical training in ophthalmology at Tongji Medical College in Wuhan in his early years, Dr. Liu Qing was selected to participate in the EU Marie Curie Young Scholars Training Program to complete the interdisciplinary research of the Retinal Neurobiology-Visual Regulation Program and received his Ph.D. from the University of Leipzig, Germany.
: This course is free and open, scan the QR code below to add Sina Pharmaceutical Live Assistant, get live link.
(Note: Name and Company)